3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

In 2019, the FDA granted approval to 48 novel drugs. As in the past years, several approvals were for cancer drugs. These apart, the agency's approvals included treatment options for patients living with cystic fibrosis, sickle cell disease and rare muscular disorders. Important approvals of non-cancer drugs were for Caplyta for schizophrenia, Nourianz for Parkinson’s disease patients experiencing “off” episodes, Vyondys 53 to treat some patients with Duchenne muscular dystrophy and Oxbryta for sickle cell disease, among others.